ライフサイエンスコーパス: treatment with

1 ize cutoff was reduced from 35 to 10 nm post-treatment with 0.8% NaOH for 20 min.

2 Treatment with 20% beeswax was the most suitable for ind

3 Patients with available bone scans before treatment with (223)Ra and at treatment discontinuation

4 Treatment with 3P10 reverses excessive lipid oxidation i

5 Supporting this, treatment with 4-phenylbutyrate, a well-known chemical c

6 ents screened, 847 were randomly assigned to treatment, with 566 patients in the pembrolizumab-chemot

7 cids give aqueous dianhydride macrocycles on treatment with a carbodiimide.

8 umor and an early decrease in flux following treatment with a chemotherapeutic drug.

9 Finite, short-duration treatment with a clinically relevant dose of GS-9688 is

10 d feasibility of pairing a potentially ideal treatment with a compound that improves its brain accumu

11 These tumors were sensitive to treatment with a cytotoxic substrate of NAT2 (6-(4-amino

12 The authors show that treatment with a DNA hypomethylating agent causes profou

13 isease or are a result of disease and/or its treatment with a gluten-free diet (GFD).

14 Treatment with a high dose of granulocyte colony-stimula

15 In vitro studies showed that treatment with a miR-216a inhibitor nanodrug suppressed

16 whose disease had progressed during previous treatment with a next-generation hormonal agent, those w

17 Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

18 Combined treatment with a polypill plus aspirin led to a lower in

19 ppaB activation after LPS treatment, whereas treatment with a potent inhibitor of the mitochondrial p

20 lphalan and stem cell transplantation and/or treatment with a proteasome inhibitor.

21 Both depletion of Pyk2 and treatment with a Pyk2 kinase inhibitor increased viral D

22 ot reduce quality of life when compared with treatment with a second androgen signalling-targeted inh

23 Treatment with a selective GR modulator (sGRm) normalize

24 ir combinations to chondrocytes, enabling OA treatment with a single injection of low drug doses and

25 inical centers and were assigned randomly to treatment with a tube shunt (350-mm(2) Baerveldt glaucom

26 rease in plasma viremia, respectively, after treatment with a V3 loop bnAb.

27 d whether it should be managed with surgical treatment, with ablative techniques, or with watchful wa

28 Accordingly, treatment with adenosine or ATPgammaS increased oxygen s

29 This effect was enhanced by co-treatment with adenoviral vectors encoding SOX17.

30 Treatment with adipogenic medium induced a significant i

31 Surgery is the preferred mode of treatment, with adjuvant chemoradiotherapy used for mali

32 to suprachoroidally injected CLS-TA or sham treatment, with administrations at day 0 and week 12.

33 nd HER2 protein levels, respectively, during treatment with agents to which the model was resistant (

34 recommend to focus diagnosis and respective treatment with AIT primarily to birch as the representat

35 petent cancer cell pairs to demonstrate that treatment with alpha-ketoglutarate (aKG) esters elicits

36 However, repeated treatments with alpha-galactosylceramide, the prototypic

37 bition deficits, suggesting that longer term treatment with alpha7 nAChR agonists for these deficits

38 Treatment with alsterpaullone (ALP) results in acquiring

39 Treatment with aminoglycosides such as streptomycin or g

40 ated with antipsychotics) undergoing initial treatment with amisulpride as part of the OPTiMiSE (Opti

41 e., de novo HF vs. worsening chronic HF) and treatment with an ACE inhibitor or ARB (i.e., ACE inhibi

42 anges in mucosal thickness (MT) 1 year after treatment with an acellular dermal matrix (ADM).

43 Conventional treatment with an anti-PD-L1 mAb had no significant anti

44 s for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested

45 Rab27b KD also decreased LC3 turnover after treatment with an autophagosome-lysosome fusion inhibito

46 with subsequent development of T790M during treatment with an EGFR inhibitor.

47 We found that systemic treatment with an mGlu(2) or mGlu(3) NAM rapidly activat

48 Importantly, treatment with an NLRP3 inhibitor reduced skin phenotype

49 duals in the United States require long-term treatment with an oral anticoagulant.

50 In addition, treatment with anti-IL-17A and -F was found to reduce ps

51 In contrast, treatment with anti-integrin alpha3 mAb KU44.22B inhibit

52 Treatment with anti-vascular endothelial growth factor a

53 Early rhythm control included treatment with antiarrhythmic drugs or atrial fibrillati

54 idence regarding the appropriate duration of treatment with antibiotic agents in children with pneumo

55 Treatment with antibiotics such as doxycycline or chlora

56 sufficient for colonization resistance after treatment with antibiotics.

57 liably predicted after either vaccination or treatment with antibodies-regardless of what virus is th

58 Treatment with anticonvulsants and age were associated w

59 ances are common in patients with SCZ before treatment with antipsychotic drugs.

60 enotypes of SCZ, as well as with response to treatment with antipsychotics.

61 s these cells can persist despite decades of treatment with antiretroviral therapy (ART).

62 apy is generally considered after failure of treatment with antithyroid drugs, or when surgery is con

63 ns for screening for HCC in persons at risk, treatment with antivirals, and an emerging role for immu

64 Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional

65 Following first-line treatment with atezo + bev, and until better data are av

66 patients with early-stage TNBC, neoadjuvant treatment with atezolizumab in combination with nab-pacl

67 d fentanyl self-administration on the day of treatment, with attenuation lasting for up to 2 weeks af

68 child mortality in communities with biannual treatment with azithromycin remain unclear.

69 avir marboxil-from patients before and after treatment with baloxavir marboxil in Japan.

70 ynthetic insecticide positive control) while treatments with bare earth margin or sprayed with water

71 Treatment with BAT product at <=2 days of symptom onset

72 an study in postmenopausal women, once daily treatment with BAY 1214784 effectively lowered plasma lu

73 re are other emerging reports that show that treatment with benralizumab(2) and dupilumab(3) is not a

74 After treatment with beta-lapachone, there was a change in (64

75 Background Relevance of antiangiogenic treatment with bevacizumab in patients with glioblastoma

76 Add-on treatment with BIO for only 4 weeks attenuates progressi

77 p plant margins and in corresponding sprayed treatments (with botanical or synthetic insecticide posi

78 150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune check

79 atory events should they arise in nAMD after treatment with brolucizumab or other anti-VEGFs.

80 He was placed on a 6 weeks course of topical treatment with budesonide, which needed to be extended d

81 lstein calves and maintained for 24 h before treatment with CC (0, 10, 100, 1000 mumol/L) and DLM (0,

82 t of tumor regression induced by combination treatment with CEA-TCB/CEA-4-1BBL in MKN-45 tumor-bearin

83 In addition, treatment with cGMP significantly enhanced Ryr2 expressi

84 ility to restrict fungal growth, even during treatment with chemical inhibitors that disrupt neutroph

85 ICD can be induced by treatment with chemotherapeutics.

86 Furthermore, treatment with CI- and SEC-exosomes leads to differentia

87 e was used to explore the effect of delaying treatment with ciprofloxacin and levofloxacin on efficac

88 Treatment with ciprofloxacin and levofloxacin was initia

89 ell lung cancer (NSCLC) explant models after treatment with clinically relevant doses of cisplatin.

90 Treatment with comprehensive disease-modifying pharmacol

91 ue of geriatric assessment in the context of treatment with contemporary systemic therapies such as i

92 In this mouse model, treatment with corticosteroid allows for initial prolife

93 26.6% higher, respectively, than those of a treatment with cover crops and no chicken grazing (- C).

94 on in patients with severe AKI regardless of treatment with CRRT.

95 With surgery only as reference, treatment with CT significantly reduced the second TC ri

96 g the natural history of hepatitis B, and on treatment with current and new agents, could characteriz

97 Treatment with currently available drugs poses treatment

98 .548; 95% CI, 0.337-0.891; p = 0.015), while treatment with cyclosporine was associated with increase

99 7 enhanced MMP-2 expression in HGFs, whereas treatment with cyclosporine-A, which inhibited CD147 exp

100 Additionally, treatment with D-serine reduces astrocyte counts in the

101 Curative treatment with DAA attenuated the liver stiffness and in

102 Depleting senescent HSCs by 'senolytic' treatment with dasatinib/quercetin or ABT-263 inhibits t

103 OVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucoc

104 In summary, treatment with DGAT1 or DGAT2 specific inhibitors result

105 uoro substituent is exchanged for hydride by treatment with DIBAL-H, generating hydridophosphoranes 1

106 er and little delay between the two types of treatment with different pulse duration is critical to g

107 Combining GDNF treatment with digestion of inhibitory CSPGs did not hav

108 ) infection, there are currently no approved treatments with direct-acting antiviral agents.

109 damage responses and cell survival following treatment with DNA-damaging agents and, as such, may pla

110 Combined treatment with DNMTi and dasatinib targeted both Hippo-d

111 Further, treatment with DON decreased hyaluronan and collagen in

112 Treatment with doxycycline for 5 days resulted in a decr

113 od of infected patients for 10-59 days until treatment with doxycycline.

114 s in high molecular mass (HMM) species after treatment with DPTA or bortezomib + DPTA, in contrast to

115 Secondary treatment with EBV-CTLs restricted by a different HLA al

116 ting the host intestinal immune responses by treatment with either a healthy fecal microbiota transpl

117 Patients were randomly assigned (1:1) to treatment with either an ambulatory device or standard g

118 Patients received crossover treatment with either half-dose PDT or HSML.

119 ed study randomizing subjects to 12 weeks of treatment with either JNJ-42165279 (25 mg daily) or plac

120 In this study, treatment with either of two BMP inhibitors reduced hepa

121 KE21 (OsWAKL21.2), is up-regulated following treatment with either Xanthomonas oryzae pv oryzae (a ba

122 tion-induced effector processes, relative to treatments with either metformin or 2-DG alone.

123 type 2 diabetes were studied after 4 weeks' treatment with empagliflozin and placebo in a randomized

124 vels increased the likelihood of response to treatment with empagliflozin.

125 We found that treatment with everolimus, an inhibitor of the mTOR path

126 Both mechanisms may be amenable to targeted treatment with existing drugs.

127 We demonstrate that treatment with FDA-approved HCQ leads to decreased muscl

128 The treatment with FDC of sofosbuvir and daclatasvir achieve

129 In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD

130 In alpha2delta-1 gene KO mice, treatment with FK506 failed to increase the frequency of

131 Furthermore, treatment with FK866, a selective inhibitor of the NAD(+

132 slows bacterial growth more effectively than treatment with free lysozyme.

133 T cell depletion in blood and lungs but only treatment with FTY720 led to cryptococcal reactivation.

134 This study was adequately powered, but treatment with gabapentin did not result in significantl

135 bility, of whom 70 were randomly assigned to treatment with gemcitabine alone (36 patients) or gemcit

136 These data suggest that long-term treatment with gemcitabine leads to extensive reprogramm

137 detectable HCV RNA 12 weeks after completing treatment with glecaprevir and pibrentasvir), adverse ev

138 re deemed likely related to HCV infection or treatment with glecaprevir and pibrentasvir.

139 hage (SAH) by follow-up on intensive medical treatment, with guideline-based monitoring/management.

140 Treatment with GX-188E therapeutic vaccine plus pembroli

141 drug following irradiation with UV light or treatment with H(2)O(2).

142 More generally, treatment with H2A and the pore-forming antibiotic polym

143 Finally, we demonstrated that combination treatment with HDAC and FAO inhibitors extended animal s

144 Treatment with HDAC6-selective inhibitors recapitulates

145 response to environmental stressors such as treatment with heat, chemicals, or virus elicitors of UP

146 ion improved significantly after 12 weeks of treatment, with higher adherence than that of available

147 y to match subgroups of patients to specific treatments with higher likelihood of clinical success.

148 The most effective treatments, with highest cure rates, are also cost-effec

149 8L265P disease were randomly assigned 1:1 to treatment with ibrutinib or zanubrutinib.

150 Treatment with icatibant (bradykinin-B2-antagonist) or a

151 Given current evidence, treatments with ICERs above the range $100 000 to $150 0

152 ans-frame peptides at the cell surface after treatment with IFNgamma.

153 Treatment with immune checkpoint blockade (ICB) has revo

154 static urothelial carcinoma who benefit from treatment with immune checkpoint inhibitors, either alon

155 une deficiencies, as their health depends on treatment with immunoglobulin preparations that need to

156 agents; (3) combination therapy; and (4) no treatment with immunosuppressive agents (control group).

157 owever, some of these patients need lifelong treatment with immunosuppressive medications to maintain

158 LUSIONS: In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab red

159 support the additive benefit of combination treatment with INCS and intranasal antihistamines in bot

160 in the fibroblast cocultures by combination treatment with inhibitors of MTOR or the antiapoptotic p

161 une response to EBV in low-grade LYG include treatment with interferon-alpha2b, whereas high-grade di

162 Treatment with interleukin (IL)-22, a cytokine with mult

163 12 cAMR patients who failed standard of care treatment with intravenous immune globulin + rituximab w

164 inhibitor therapy and ultimately amenable to treatment with intravitreal anti-vascular endothelial gr

165 The endophthalmitis responded well to treatment with intravitreal antibiotics.

166 disease currently have only hospitalization treatment, with its high mortality, available to them.

167 Treatment with IV immunoglobulins was associated with im

168 Studies have demonstrated early treatment with laminin-111 protein results in an increas

169 Strikingly, the combinatorial treatment with lapatinib [dual kinase inhibitor of EGFR

170 sites based on alternating sequential sample treatments with legumain and PNGaseF and vice versa.

171 pproaches such as deep brain stimulation and treatment with levodopa-carbidopa enteral suspension can

172 e in serum cholesterol after 4 weeks of post-treatment with lipoMSN carrying both pcsk9 and angptl3-t

173 lasticity, deficits that could be rescued by treatment with lithium.

174 ical outcome of these events, individualized treatment with locally available standard of care should

175 Treatment with loop diuretics, the current cornerstone o

176 Perinatal treatment with lopinavir boosted by ritonavir (LPV/r) is

177 Treatment with lovastatin, a mevalonate biosynthesis inh

178 Subsequent treatment with low-dose EPO triggered robust RBC product

179 ere associated with decreased probability of treatment with LT, including cataract surgery (OR, 0.31;

180 We show that treatment with lysozyme-functionalized origami slows bac

181 We evaluated the effect of OSAHS treatment with MADs on the myocardium.

182 a only) and none occurred after in-community treatment with magnesium sulfate or during transport to

183 P uptake were greater in the heterogeneous P treatment with maize/faba bean than with maize/maize sys

184 possible association of dyslipidemia and its treatment with meibomian gland (MG) morphologic changes

185 and 10% daily increase, respectively), while treatment with meropenem, piperacillin-tazobactam, and o

186 d studies have demonstrated that combination treatment with metformin and 2-DG was efficacious in dam

187 adverse effects occurred after in-community treatment with methyldopa (one [2%] of 51; India only) a

188 y, in a subset of patients with comorbid PD, treatment with mGluR2 PAM resulted in complete remission

189 Over the first 6 cycles of treatment with midostaurin (ie, 6 months), patients expe

190 QOL and symptom burden were assessed during treatment with midostaurin by using the 12-Item Short-Fo

191 isk group and white blood cell (WBC) counts; treatment with midostaurin had no influence.

192 Treatment with MODULEN did not reverse inflammation or f

193 The results show that chronic treatment with morphine results in a surprising and hete

194 evated plasma triglycerides and cholesterol, treatment with MSU-42011 did not increase these biomarke

195 In a murine model of AML, dual treatment with MTP-PE and IFN-gamma led to a significant

196 d impaired cell growth that are corrected by treatment with myriocin, a sphingolipid synthesis inhibi

197 Treatment with naked anti-CD26 mAb KU44.13A did not have

198 ase series at a single academic center where treatment with netarsudil produced a particular pattern

199 Both CO and NO inhibited respiration, and treatment with Ngb-H64Q-CCC (100 and 50 mum, respectivel

200 Six subjects tolerated a total of 17 FUS treatments with no adverse events and neither cognitive

201 significantly less numerous in all unsprayed treatments with non-crop plant margins and in correspond

202 Treatment with NS9283 restores the rapid onset of the po

203 posterior capsule opacification compared to treatment with NSAIDs alone.

204 We compare how chronic and acute treatments with omega-3 FAs differentially trigger pathw

205 sed or had refractory disease after previous treatment with one to three systemic regimens (with at l

206 Maintenance treatment with opioid agonists (buprenorphine, methadone

207 (Women's Health Initiative Hormone Therapy), treatment with oral conjugated equine estrogens and medr

208 travenous CaNa(2)EDTA for 2 days followed by treatment with oral D-penicillamine for 90 days.

209 The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioratio

210 neuroprotection in cancer patients requiring treatment with oxaliplatin.

211 PDAC metastases were investigated following treatment with P-AscH(-).

212 ght heart catheterization were randomized to treatment with PADN (PADN group; n = 25) using remote ma

213 t main coronary artery disease randomized to treatment with PCI or CABG in the SYNTAX trial.

214 Treatment with PD-L1 antibody also reduces Treg and Breg

215 The effect of treatment with platinum-based chemotherapy on CTGCT risk

216 Treatment with PN controlled seizures and improved survi

217 treatment should be suspended and intensive treatment with potent corticosteroids (topical, subtenon

218 with vamorolone than have been reported for treatment with prednisone and deflazacort, and that vamo

219 ir HVPG measured before and at 1-3 months of treatment with propranolol/nadolol plus endoscopic band

220 However, treatment with PRRT resulted in normalization of calcium

221 rofiles of "Laba" garlic were modified after treatments, with pungent compounds decreased to non-dete

222 In contrast, treatment with pure EGCG in DS mouse models did not impr

223 De novo treatment with RAASi in patients hospitalized with COVID

224 We further demonstrate that treatment with radiation and polyinosinic-polycytidylic

225 in the degradation of cortical ER following treatment with rapamycin, a drug that mimics starvation.

226 Treatment with recombinant CD163 was able to neutralize

227 Treatment with recombinant Gal1 restored tolerogenic mec

228 potential for physicians to timely initiate treatment with reduced mortality and costs.

229 t has been hypothesized that the benefits of treatment with renin-angiotensin system inhibitors in SA

230 nowledge, this is the first reported case of treatment with retrobulbar triamcinolone injections.

231 wn.Objectives: To evaluate whether postnatal treatment with rhIGF-1 (recombinant human IGF-1)/BP3 (bi

232 y affected by cell growth rates and by prior treatment with rifampicin.

233 e started or to receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyra

234 Treatment with RIPK1 antisense oligonucleotides led to a

235 Treatment with S/V was well-tolerated.

236 Post extubation treatment with S107, a Rycal drug that stabilizes the ry

237 Treatment with salubrial had no significant effect, whil

238 ctivity in PGRN mutant neurons is rescued by treatment with saposin C.

239 monstrated along with a frequent concomitant treatment with several QT-prolonging drugs.

240 Treatment with SGLT2 inhibitors is distinguished by 2 in

241 overcome drug resistance encountered during treatment with single agent alone.

242 mice showed that early treatment with sirolimus reduced the development of glom

243 Pre-treatment with SKF-83566, a D1 receptor antagonist, atte

244 computed tomography scan during 52 weeks of treatment with SNF472 or placebo, in addition to standar

245 In clinical trials, HCV salvage treatment with Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/

246 predictor of left ventricular remodeling was treatment with sonothrombolysis: the control group was m

247 osialotetrahexosylganglioside levels, and co-treatment with standard chemotherapeutics sensitized cel

248 Treatment with steroids allowed a rapid improvement in s

249 Postoperative treatment with steroids among patients undergoing uncomp

250 tly induced apoptotic rates during cisplatin treatment with strongest induction of apoptosis in each

251 evidence of a beneficial effect from several treatments, with substantially reduced doses than previo

252 based financing, and intermittent-preventive-treatment with sulphadoxine-pyrimethamine (IPTp-SP).

253 recently approved for Type-II diabetes (T2D) treatment with superior hypoglycemic effect while also i

254 and neck cancer implies a multidisciplinary treatment with surgery, radiotherapy and chemotherapy.

255 tudy of Liver Diseases who were eligible for treatment with TACE were enrolled.

256 Treatment with tafamidis is projected to produce substan

257 Treatment with Tat-A and Tat-B caused membrane disruptio

258 patients who had residual disease following treatment with taxanes plus an anthracycline, suggesting

259 Continuous treatment with TFP and a single dose of radiation reduce

260 Treatment with TGF-beta1 elicited distinct phenotypes on

261 g/L Cu, which was subjected to hydrothermal treatment with the addition of levulinic acid (LA).

262 and improved the synergistic cytotoxicity of treatment with the alkylating agent temozolomide in comb

263 d in AD amyloid plaques in human brains, and treatment with the antiviral acyclovir (ACV) was reporte

264 Treatment with the cAMP analogue Br-cAMP to mimic cAMP r

265 Treatment with the clathrin-mediated endocytosis inhibit

266 hors present empirical evidence showing that treatment with the complement inhibitor compstatin Cp40

267 at the amount of platinum in the brain after treatment with the conjugate is 15-fold greater than wit

268 Treatment with the CSF1R inhibitor GW2580 significantly

269 ese changes are attenuated or reversed after treatment with the DDR1 inhibitor, nilotinib.

270 Neonatal treatment with the ER stress-relieving drug tauroursodeo

271 that increasing neuronal activity by chronic treatment with the FDA-approved potassium channel blocke

272 In cultured cardiomyocytes, treatment with the FOXO1 inhibitor AS1842856 or transfec

273 investigated TNTs in CML cells and following treatment with the highly effective CML therapeutics tyr

274 In line with this finding, treatment with the histone deacetylase inhibitor givinos

275 the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine Trial).

276 Upon treatment with the immunosuppressant azathioprine there

277 DHCR7 deficiency or treatment with the natural product 7-dehydrocholesterol

278 oustic stimuli, are replicated by short-term treatment with the NMDAR antagonist MK-801, suggesting t

279 Patients were randomized 3:3:3:2 to treatment with the PDS filled with ranibizumab 10-mg/ml,

280 ), exposure to a novel environment and acute treatment with the psychostimulant drug, amphetamine.

281 ositive score [CPS] >=1 or <1), and previous treatment with the same class of chemotherapy in the neo

282 In multivariate analysis, treatment with the shorter antibiotic course was not sig

283 Downregulation of Skp2 or treatment with the Skp2-specific inhibitor C1 revealed t

284 nnomatosis-associated N/S HNST, and targeted treatment with the small-molecule ERBB inhibitor lapatin

285 Intranasal treatment with the synthetic glucocorticoid fluticasone

286 Treatment with therapeutic hypothermia (TH) improves the

287 t data did not address the issue of how long treatment with these antimicrobials would remain effecti

288 treatment of severe pain; however, prolonged treatment with these drugs leads to the development of t

289 essment of retinal morphology, we found that treatment with these flavonoids prior to light insult re

290 Treatment with TLR4 inhibitor resulted in lower liver in

291 Treatment with TNF inhibitors in RA patients reverses th

292 Off-label treatment with tocilizumab restored the cytotoxic potent

293 easurement was based on time-to-thrombolytic treatment with tPA (tissue-type plasminogen activator).

294 Their treatment with trifluoroacetic or hydrochloric acid affo

295 One day of treatment with tropisetron improved both cognitive and P

296 Recently, treatments with two drug classes targeting CFTR-one boos

297 gery, and lately also to select patients for treatment with type 2 biologics.

298 In addition, long-term treatment with typical or atypical antipsychotics, under

299 ulcerative colitis (UC), in which first-time treatment with vedolizumab was initiated.

300 post-injury, the animals were randomized to treatment with vehicle (n = 6) or 0.10-0.17 mg/kg/day of